If I was Mensa, after I shot myself, I would start posting as a ridiculous fool. I may use the name vringostarrrr.
are you pathetic for focusing on an anonymous poster and not making money? Yes
I'm usually proud of what I did in the toilet. As to investing. seriously all you need to do is ask, use your Ontop I.D and I will answer any questions you may have about ONCS.
tl, we also need to consider that Anti-PD-1 is projected to be a $3b a year industry. Once ONCS proves with melanoma their ability to greatly increase response rates, ONCS will be breaking into many new markets, could wind up with $500m-$1b a year revenues upon approval.
I would be more than happy to answer any and all questions that you have, and explain why each point you make is both irrelevant and out dated. All you have to do is ask the question with your Ontop I.D. That' the Only I.D. I will respond to.
good but rather a Herculean task. I researched about 15 different companies but data points, goals, etc, are so varied that a direct comparison is impossible. I'm going to hold off till ONCS has some new developments then do something.
IL-12 has better efficacy and fewer SAE's as is. If IL-21 was electroporated, it too would have fewer SAE's, but would still have the lower efficacy. You can not beat 0 SAE's, so unless they have something that has better efficacy, or more importantly, the ability to create higher TIL level's I would be unconcerned.
funny how you and all your other alias' use the same ridiculous bear arguments that no serious investor would pay any attention to. But hey, take some time off, this week will be boring.
if you are going to invest in biotech, you should have at least a basic understanding of "method of action". If you ask this with your Ontop I.D. I might consider explaining it to you
he's not really worth responding to anymore. Its like he's trying to be a spokesman for the worlds worst investors.
it really does not matter when Mk-3475 gets approved. If a partnership deal get signed the partner will provide the drug. Approval of an AntiPD1 drug is only important if ONCS has to buy it on the open market